Flt3-Ligand, Sf9 Protein
234€ (2 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Flt3-Ligand, Sf9 Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx263192
tested applications
SDS-PAGE
Description
Flt3-Ligand, Sf9 Protein is a recombinant cytokine.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Flt3 Ligand Sf9 |
| Origin | Human |
| Conjugation | Unconjugated |
| Expression | Recombinant |
| Purity | > 95% (SDS-PAGE and RP-HPLC) |
| Size 1 | 2 µg |
| Size 2 | 10 µg |
| Size 3 | 100 µg |
| Form | Lyophilized |
| Tested Applications | SDS-PAGE |
| Availability | Shipped within 5-10 working days. |
| Dry Ice | No |
| UniProt ID | P49771 |
| Alias | Receptor-type tyrosine-protein kinase FLT3,FLK2,STK1,CD135,FLK-2,FL cytokine receptor,Fetal liver kinase-2,Fms-like tyrosine kinase 3,Stem cell tyrosine kinase 1 |
| Background | Protein FLT3 |
| Status | RUO |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
FLT3 (Fms-like tyrosine kinase 3), also known as CD135, is a cell-surface receptor primarily expressed on hematopoietic progenitor cells in the bone marrow and on certain immune cells, such as dendritic cells. Classified as a receptor tyrosine kinase (RTK), FLT3 belongs to the type III RTK family, which also includes the KIT, PDGFR, and CSF1R proteins. FLT3 plays a central role in the regulation of hematopoiesis by promoting the survival, proliferation, and differentiation of hematopoietic stem and progenitor cells (HSPCs). The FLT3 ligand (FLT3L) is the primary growth factor that binds to and activates FLT3, resulting in downstream signaling essential for immune cell development. FLT3 has attracted significant scientific interest due to its implication in hematologic malignancies, especially acute myeloid leukemia (AML). Mutations in the FLT3 gene, particularly internal tandem duplications (ITDs) and point mutations in the tyrosine kinase domain (TKD), are common in AML and are associated with a poor prognosis. Consequently, FLT3 is a prominent target in therapeutic research, with several FLT3 inhibitors under development or in clinical use for the treatment of FLT3-mutated AML.
Related Products
Human FLT3(Receptor-type tyrosine-protein kinase FLT3) ELISA Kit
Ver Producto
Mouse FLT3(Receptor-type tyrosine-protein kinase FLT3) ELISA Kit
Ver Producto